The combined treatment of TRAIL and paclitaxel, cabazitaxel or docetaxel significantly increased the apoptotic effect on PC3 and DU145 prostate cancer cells compared to TRAIL or taxane used alone. This evidence concerns the gene TNFSF10 and prostate carcinoma.